Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Sees Significant Increase in Short Interest

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the target of a large increase in short interest in May. As of May 29th, there was short interest totaling 8,114 shares, an increase of 381.3% from the May 14th total of 1,686 shares. Based on an average trading volume of 14,113 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.7% of the shares of the stock are short sold.

Global X Genomics & Biotechnology ETF Stock Down 2.0%

GNOM stock opened at $47.92 on Thursday. The company’s 50-day simple moving average is $46.31 and its 200-day simple moving average is $46.33. Global X Genomics & Biotechnology ETF has a 52-week low of $32.08 and a 52-week high of $51.42. The firm has a market cap of $53.67 million, a P/E ratio of -20.48 and a beta of 1.21.

Institutional Investors Weigh In On Global X Genomics & Biotechnology ETF

Several hedge funds have recently modified their holdings of GNOM. IFP Advisors Inc boosted its stake in shares of Global X Genomics & Biotechnology ETF by 20.8% during the 3rd quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock worth $110,000 after acquiring an additional 489 shares in the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Global X Genomics & Biotechnology ETF by 30.9% during the 2nd quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock worth $164,000 after acquiring an additional 4,615 shares in the last quarter. Sei Investments Co. boosted its stake in shares of Global X Genomics & Biotechnology ETF by 110.4% during the 2nd quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock worth $194,000 after acquiring an additional 12,105 shares in the last quarter. Wealth Management Partners LLC purchased a new stake in shares of Global X Genomics & Biotechnology ETF during the 1st quarter worth about $244,000. Finally, Creative Financial Designs Inc. ADV boosted its stake in shares of Global X Genomics & Biotechnology ETF by 4.1% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 12,124 shares of the company’s stock worth $551,000 after acquiring an additional 481 shares in the last quarter. 56.95% of the stock is owned by hedge funds and other institutional investors.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.